Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Daiichinkyo Co's Enterprise Value is $63,966 Mil.
Daiichinkyo Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $1,692 Mil. Therefore, Daiichinkyo Co's EV-to-EBIT ratio for today is 37.81.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Daiichinkyo Co's Enterprise Value is $63,966 Mil.
Daiichinkyo Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $2,101 Mil. Therefore, Daiichinkyo Co's EV-to-EBITDA ratio for today is 30.45.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Daiichinkyo Co's Enterprise Value is $63,966 Mil.
Daiichinkyo Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $10,985 Mil. Therefore, Daiichinkyo Co's EV-to-Revenue ratio for today is 5.82.
Daiichinkyo Co Enterprise Value Historical Data
The historical data trend for Daiichinkyo Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Daiichinkyo Co's Enterprise Value
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Enterprise Value falls into.
Daiichinkyo Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Daiichinkyo Co's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (OTCPK:DSNKY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Daiichinkyo Co's current Enterprise Value is $63,966 Mil.
Daiichinkyo Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,692 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Daiichinkyo Co's current Enterprise Value is $63,966 Mil.
Daiichinkyo Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,101 Mil.
Daiichinkyo Co's current Enterprise Value is $63,966 Mil.
Daiichinkyo Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,985 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co Enterprise Value Related Terms
Thank you for viewing the detailed overview of Daiichinkyo Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Daiichinkyo Co (Daiichinkyo Co) Business Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DSNKY has been successfully added to your 